BDH Industries Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: BDH Industries Limited Pharmaceutical Export Portfolio Dataset — 13 Products, $5.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

BDH Industries Limited — Pharmaceutical Exporter Profile (2026) | 13 Products, $5.7M Trade | TransData Nexus

BDH Industries Limited

Indian Pharmaceutical Exporter · Nutritional Supplements Specialist · $5.7M Total Trade · DGFT Verified

BDH Industries Limited is an Indian pharmaceutical exporter with a total trade value of $5.7M across 13 products in 9 therapeutic categories. Based on 176 verified export shipments from Indian Customs (DGFT) records, BDH Industries Limited is the #1 Indian exporter in 1 product including Primaquine. Top exports include Vitamin ($1.8M), Celecoxib ($850.0K), Erythromycin ($850.0K).

BDH Industries Limited — Export Portfolio & Destination Treemap

BDH Industries Limited pharmaceutical export portfolio — 13 products across 9 therapeutic categories. Source: Indian Customs (DGFT).

Who is BDH Industries Limited? — Company Overview & Market Position

BDH Industries Limited, established in 1935 as Bombay Drug House, is a prominent Indian pharmaceutical company headquartered in Mumbai, Maharashtra. In 1990, it transitioned from a private to a public limited company, adopting the name BDH Industries Limited. The company is registered under the Corporate Identification Number (CIN) L24100MH1990PLC059299. As of the latest available data, BDH Industries has an authorized share capital of ₹75 million and a paid-up capital of ₹57.573 million.

BDH Industries specializes in the manufacture and export of therapeutic formulations, encompassing a wide range of pharmaceutical products. The company operates through two primary segments: Pharmaceuticals and Renewable Energy. In the Pharmaceuticals segment, BDH Industries offers a diverse portfolio, including analgesics, antacids, antibiotics, antifungals, and more. The Renewable Energy segment involves the operation of wind turbines, reflecting the company's commitment to sustainable practices.

What Does BDH Industries Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Vitamin$1.8M 2

Product Portfolio — Top 13 by Export Value

BDH Industries Limited exports 13 pharmaceutical products across 9 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Vitamin	Nutritional Supplements	$1.8M	36	1.3%	6
2	Celecoxib	Analgesics & Antipyretics	$850.0K	17	0.6%	13
3	Erythromycin	Antibiotics	$850.0K	17	1.1%	2
4	Tetracycline	Antibiotics	$455.6K	34	2.7%	6
5	Carvedilol	Cardiovascular	$400.0K	8	0.4%	14
6	Zinc	Vitamins & Supplements	$350.0K	7	0.4%	11
7	Primaquine	Antimalarial & Antiparasitic	$290.8K	7	17.3%	1
8	Colchicine	Lipid & Metabolism	$164.8K	6	0.8%	15
9	Morphine	Analgesics & Antipyretics	$153.3K	6	0.9%	7
10	Praziquantel	Antimalarial & Antiparasitic	$138.2K	7	4.7%	3
11	Proguanil	Antimalarial & Antiparasitic	$123.2K	4	0.0%	5
12	Bisacodyl	Gastrointestinal	$110.0K	19	1.3%	15
13	Aminophylline	Respiratory & OTC	$54.7K	8	0.9%	11

BDH Industries Limited exports 13 pharmaceutical products across 9 therapeutic categories with a total export value of $5.7M. The company is the #1 Indian exporter in 1 product: Primaquine. The top category is Nutritional Supplements (31.4% of portfolio), followed by Antibiotics (22.7%), indicating a concentrated portfolio with the top 5 products accounting for 75.9% of total export value.

BDH Industries Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

BDH Industries' manufacturing facility spans 42,500 square feet and is located in Mumbai, Maharashtra. The plant is accredited with WHO-GMP and ISO 9001:2015 standards, ensuring adherence to stringent quality and compliance protocols. The facility comprises specialized divisions, including Oncology, General Pharmaceuticals (non-sterile and sterile products), and Specialty Products. Manufacturing operations are conducted in strict accordance with Good Manufacturing Practices (GMP), with rigorous process controls and testing standards implemented at each stage of production.

3Key Leadership

The leadership team at BDH Industries Limited is headed by Ms. Jayashree Nair, who serves as the Chairperson and Managing Director. With over six decades of experience in the pharmaceutical industry, Ms. Nair has been instrumental in the company's growth and global recognition. Mr. S.C. Kachhara holds the position of Managing Director and Chief Financial Officer, bringing over 47 years of experience in the pharmaceutical sector. He has been associated with BDH Industries since 1978 and has played a pivotal role in the company's expansion and financial management. Ms. Karthika Nair serves as a Non-Executive Director, contributing her expertise in genetics and marketing to the company's strategic direction.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does BDH Industries Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

BDH Industries Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully registered its products with respective drug administrations in these regions, demonstrating compliance with stringent regulatory standards. This global footprint underscores BDH Industries' commitment to providing high-quality pharmaceutical products worldwide.

2Emerging Markets

BDH Industries has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to WHO-GMP standards has facilitated access to these regions, enabling the export of its products to over 30 countries across four continents. This strategic expansion reflects BDH Industries' dedication to addressing global healthcare needs and enhancing its international presence.

3Geographic Strategy

BDH Industries Limited has strategically diversified its geographic presence to mitigate concentration risks and capitalize on growth opportunities. By exporting to over 30 countries across four continents, the company has reduced dependency on any single market, thereby enhancing its resilience against regional economic fluctuations. This diversified approach aligns with BDH Industries' strategic direction to establish a robust global footprint in the pharmaceutical industry.

BDH Industries Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

BDH Industries Limited has registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. regulatory standards. The company has also filed Abbreviated New Drug Applications (ANDAs) for its products, facilitating market access in the United States. While specific details regarding Drug Master File (DMF) filings and inspection history are not publicly disclosed, BDH Industries' adherence to WHO-GMP standards indicates a commitment to maintaining high-quality manufacturing practices.

2WHO & EU GMP

BDH Industries Limited holds WHO-GMP certification, reflecting its compliance with international manufacturing standards. This certification is crucial for exporting pharmaceutical products to various global markets, including the European Union. While specific details regarding EU GMP certificates and EDQM status are not publicly available, the WHO-GMP certification underscores BDH Industries' commitment to quality and regulatory compliance.

3CDSCO & Indian Regulatory

BDH Industries Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

BDH Industries Limited operates in a competitive pharmaceutical market, with several key players in overlapping therapeutic categories. While specific market share comparisons are not publicly available, BDH Industries' diverse product portfolio and global export reach position it as a significant competitor in the industry. The company's focus on quality manufacturing and regulatory compliance further enhances its competitive standing.

2Key Differentiators

BDH Industries Limited distinguishes itself through its long-standing history in the pharmaceutical industry, spanning over eight decades. The company's commitment to quality is evident in its adherence to WHO-GMP and ISO 9001:2015 standards. Additionally, BDH Industries' diverse product portfolio, encompassing various therapeutic categories, and its global export reach to over 30 countries, underscore its competitive advantages.

3Strategic Position

BDH Industries Limited's current strategic direction focuses on expanding its global footprint through exports and contract manufacturing partnerships. The company's adherence to international quality standards and its diverse product portfolio position it well for future growth. BDH Industries' commitment to quality and customer satisfaction suggests a strategic focus on maintaining and enhancing its position in the global pharmaceutical market.

Buyer Due Diligence Brief — Evaluating BDH Industries Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

BDH Industries Limited has a commendable track record in the pharmaceutical industry, with over 80 years of experience in manufacturing therapeutic formulations. The company's export volume and consistency are evidenced by its active presence in over 30 countries across four continents. Reliability indicators include its adherence to WHO-GMP and ISO 9001:2015 standards, reflecting a commitment to quality and compliance.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm the manufacturer's registration with the U.S. Food and Drug Administration.

WHO-GMP Certification: Ensure the manufacturer holds a valid WHO-GMP certificate, indicating compliance with international manufacturing standards.

EU GMP Certification: Verify the manufacturer's EU GMP certificate, confirming adherence to European manufacturing standards.

Frequently Asked Questions — BDH Industries Limited

How many pharmaceutical products does BDH Industries Limited export from India?

BDH Industries Limited exports 13 pharmaceutical products across 9 therapeutic categories. The top exports are Vitamin ($1.8M), Celecoxib ($850.0K), Erythromycin ($850.0K), Tetracycline ($455.6K), Carvedilol ($400.0K). Total export value is $5.7M.

What is BDH Industries Limited's total pharmaceutical export value?

BDH Industries Limited's total pharmaceutical export value is $5.7M, based on 176 verified shipments recorded in Indian Customs (DGFT) data.

In which products is BDH Industries Limited the #1 Indian exporter?

BDH Industries Limited is the #1 Indian exporter in 1 products: Primaquine (17.3% market share).

What therapeutic categories does BDH Industries Limited cover?

BDH Industries Limited exports across 9 therapeutic categories. The largest are Nutritional Supplements (31.4%, 1 products), Antibiotics (22.7%, 2 products), Analgesics & Antipyretics (17.5%, 2 products).

Get Full BDH Industries Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.